Clinical-stage biopharmaceutical company developing therapies for central nervous system disorders.
Axsome Therapeutics, Inc., a dynamic biopharmaceutical firm based in New York, focuses on pioneering therapies for central nervous system (CNS) disorders within the United States. The company's robust commercial portfolio includes Auvelity (dextromethorphan-bupropion), an innovative N-methyl-D-aspartate receptor antagonist renowned for its multimodal activity in treating major depressive disorder. Additionally, Axsome offers Sunosi (solriamfetol), a medication indicated for combating excessive daytime sleepiness in patients afflicted with narcolepsy or obstructive sleep apnea.
Axsome Therapeutics, Inc. is at the forefront of groundbreaking research and development initiatives. Their flagship candidate, AXS-05, is currently undergoing Phase III clinical trials aimed at addressing Alzheimer's disease agitation and has also completed Phase II trials for smoking cessation. Further bolstering its pipeline, the company has AXS-07, an investigational medicine that has completed Phase III trials targeting the acute treatment of migraine headaches.
Moreover, Axsome is advancing AXS-12 through Phase III trials for the management of narcolepsy, while AXS-14, a selective and potent norepinephrine reuptake inhibitor, is undergoing Phase III trials for treating conditions such as fibromyalgia. The company's compprehensive approach to drug development also includes solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has shown promise in Phase 2 trials for treating attention-deficit/hyperactivity disorder (ADHD).
In alignment with its commitment to advancing CNS therapies, Axsome Therapeutics, Inc. collaborates closely with esteemed institutions such as Duke University. This partnership focuses on evaluating AXS-05's efficacy in smoking cessation, underscoring the company's dedication to exploring new frontiers in neurological health. Since its inception in 2012, Axsome has maintained its headquarters in New York City, strategically positioning itself within a vibrant hub of biomedical innovation and research excellence.